NASDAQ$AQST
Aquestive Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter and provided an update on recent developments in its business.
Aquestive Therapeutics reported a 52% increase in total revenues to $20.1 million for the second quarter 2024, driven by increases in license and royalty revenue. The company's net loss decreased to $2.7 million, or $0.03 per share, compared to a net loss of $5.8 million, or $0.10 per share, for the second quarter 2023. Cash and cash equivalents were approximately $90 million as of June 30, 2024, and the company reaffirms cash runway into 2026.
- Anaphylm™ (epinephrine) Sublingual Film remains on track for a near-term New Drug Application (NDA) submission to the FDA.
- Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two and five with national retail distribution anticipated in the fourth quarter 2024.
- Anticipates holding epinephrine prodrug technology investor day in the coming months.
- Finishes the second quarter 2024 with cash and cash equivalents of approximately $90 million and reaffirms cash runway into 2026.
Headline financials
Revenue & EPS history
Aquestive · Revenue · Quarterly
$20.1M
Forward guidance
Aquestive is updating its full-year 2024 financial guidance based on second quarter 2024 results and updated outlook for the remainder of 2024.
Tailwinds
- Total revenue (in millions) $57 to $60
Headwinds
- Non-GAAP adjusted EBITDA loss (in millions) $20 to $23
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-0.4%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
14 / 31 earnings
Positive
+22.8%
Q3 2019
Best reaction
-44.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -1.0% | +0.0% | |
| Q4 2025 | -2.5% | -3.9% | -5.5% | |
| Q3 2025 | +2.0% | -5.2% | +6.3% | |
| Q1 2025 | -19.4% | -16.5% | +16.1% | |
| Q4 2024 | -7.5% | -5.4% | -2.9% | |
| Q3 2024 | -13.8% | -1.1% | -21.9% | |
| Q2 2024 | +4.3% | +4.3% | +28.6% | |
| Q1 2024 | -11.7% | -11.7% | -19.7% | |
| Q4 2023 | +20.3% | +16.7% | -0.5% | |
| Q3 2023 | +6.9% | +5.0% | +28.7% | |
| Q2 2023 | -7.2% | -7.2% | -24.4% | |
| Q1 2023 | +20.9% | +46.8% | +66.2% | |
| Q4 2022 | +5.6% | -1.4% | +45.3% | |
| Q3 2022 | -3.4% | +0.6% | +7.5% | |
| Q2 2022 | -2.2% | +2.7% | +50.5% | |
| Q1 2022 | +0.7% | -14.2% | -32.6% | |
| Q4 2021 | -4.8% | -12.6% | -18.0% | |
| Q3 2021 | +12.6% | +10.7% | +2.7% | |
| Q2 2021 | +11.2% | +12.1% | +39.6% | |
| Q1 2021 | -3.3% | -14.1% | -6.8% | |
| Q4 2020 | +11.5% | +24.6% | +11.5% | |
| Q3 2020 | +3.6% | +4.9% | +29.6% | |
| Q2 2020 | +4.0% | +10.5% | +26.5% | |
| Q1 2020 | -4.0% | +14.4% | +14.2% | |
| Q4 2019 | -44.2% | -55.2% | -16.0% | |
| Q3 2019 | +22.8% | +26.8% | +95.8% | |
| Q2 2019 | +12.5% | +22.7% | +14.1% | |
| Q1 2019 | -11.4% | -14.9% | -29.9% | |
| Q4 2018 | -14.4% | -8.3% | -18.7% | |
| Q3 2018 | -1.1% | -7.8% | -15.1% | |
| Q2 2018 | -0.3% | +5.3% | -7.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro